clinical trial · NCT06641414
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Higher-risk Myelodysplastic SyndromeLisaftoclax (APG-2575)Azacitidine InjectionPlacebo
brief summary
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
started
Jan 22, 2025
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Nov 20, 2025
detailed description
This study intends to enroll patients with HR-MDS to receive the therapy of Lisaftoclax (APG-2575) combined with azacitidine (AZA) or placebo combined with azacitidine.
official title
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol